Goldman Sachs Group Inc Taysha Gene Therapies, Inc. Transaction History
Goldman Sachs Group Inc
- $706 Billion
- Q2 2025
A detailed history of Goldman Sachs Group Inc transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 12,587,700 shares of TSHA stock, worth $38.6 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,587,700
Previous 359,007
3406.25%
Holding current value
$38.6 Million
Previous $499,000
5727.05%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding TSHA
# of Institutions
154Shares Held
244MCall Options Held
107KPut Options Held
17K-
Rtw Investments, LP New York, NY25MShares$76.8 Million0.89% of portfolio
-
Ra Capital Management, L.P. Boston, MA23.6MShares$72.3 Million1.19% of portfolio
-
Avoro Capital Advisors LLC New York, NY21.7MShares$66.6 Million0.91% of portfolio
-
Morgan Stanley New York, NY16.9MShares$51.8 Million0.0% of portfolio
-
Octagon Capital Advisors LP New York, NY12.6MShares$38.7 Million11.04% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $148M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...